These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1568787)

  • 1. Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion.
    Jayaram HN; Lapis E; Tricot G; Kneebone P; Paulik E; Zhen W; Engeler GP; Hoffman R; Weber G
    Int J Cancer; 1992 May; 51(2):182-8. PubMed ID: 1568787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot G; Weber G
    Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
    Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
    Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
    Wright DG; Boosalis MS; Waraska K; Oshry LJ; Weintraub LR; Vosburgh E
    Anticancer Res; 1996; 16(6A):3349-51. PubMed ID: 9042310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of continuous infusion 6-thioguanine in patients with acute leukemia.
    Powell BL; Lyerly ES; Motsinger CP; Cruz JM; Chorley HM; Hurd DD; Cooper MR
    Leukemia; 1995 May; 9(5):770-3. PubMed ID: 7769838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical toxicity associated with tiazofurin.
    Grem JL; Rubinstein L; King SA; Cheson BD; Hawkins MJ; Shoemaker DD
    Invest New Drugs; 1990 May; 8(2):227-38. PubMed ID: 2200759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
    Larson RA; Geller RB; Janisch L; Milton J; Grochow LB; Ratain MJ
    Cancer Chemother Pharmacol; 1995; 36(3):204-10. PubMed ID: 7781139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
    Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.
    Wilhelm M; O'Brien S; Rios MB; Estey E; Keating MJ; Plunkett W; Sorenson M; Kantarjian HM
    Leuk Lymphoma; 1999 Aug; 34(5-6):511-8. PubMed ID: 10492074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
    Mirro J; Kalwinsky DK; Grier HE; Santana VM; Mason C; Murphy SB; Dahl GV
    Cancer Chemother Pharmacol; 1989; 24(2):123-7. PubMed ID: 2731312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.
    Seiter K; Feldman EJ; Halicka HD; Traganos F; Darzynkiewicz Z; Lake D; Ahmed T
    J Clin Oncol; 1997 Jan; 15(1):44-51. PubMed ID: 8996123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
    Malek K; Boosalis MS; Waraska K; Mitchell BS; Wright DG
    Leuk Res; 2004 Nov; 28(11):1125-36. PubMed ID: 15380335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
    Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical issues in chemotherapy with tiazofurin.
    Weber G
    Adv Enzyme Regul; 1989; 29():75-95. PubMed ID: 2699155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
    Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
    Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
    Kantarjian HM; Gandhi V; Kozuch P; Faderl S; Giles F; Cortes J; O'Brien S; Ibrahim N; Khuri F; Du M; Rios MB; Jeha S; McLaughlin P; Plunkett W; Keating M
    J Clin Oncol; 2003 Mar; 21(6):1167-73. PubMed ID: 12637486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous infusion chemotherapy with epirubicin and vincristine in relapsed and refractory acute leukemia.
    Liso V; Specchia G; Pavone V; Capalbo S; Dione R
    Acta Haematol; 1990; 83(3):116-9. PubMed ID: 2109448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
    Lee EJ; Reck K; Carter C; Hodges S; Schiffer CA
    Leukemia; 1993 Oct; 7(10):1500-3. PubMed ID: 8412310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.